Table 2.
Clinically investigated rabbit antibodies for therapeutic applications.1
| Antibody | Format2 | Names | Manufacturers and developers | Antigen | Indication | Year of FDA approval or highest stage of clinical trials |
|---|---|---|---|---|---|---|
| rabbit pAb | Polyclonal IgG | anti-thymocyte globulin [rabbit] (ATG; Thymoglobulin®) | Sanofi, Genzyme | human thymocytes | transplantation (prophylaxis and treatment) | 1998 |
| humanized rabbit mAb | scFv | brolucizumab (ESBA1008) | Novartis, Alcon, ESBATech | human VEGF | eye diseases (treatment) | Phase III |
| humanized rabbit mAb | aglycosylated IgG1 | eptinezumab (ALD403) | Alder | human CGRP | migraine (prophylaxis) | Phase III |
| humanized rabbit mAb | scFv | LME636 (ESBA1622) | Novartis, Alcon, ESBATech | human TNFα | eye diseases (treatment) | Phase II |
| humanized rabbit mAb | IgG1 | sevacizumab (APX003; TK001) | Simcere, Jiangsu T-mab, Apexigen, Epitomics | human VEGF | cancer (treatment) eye diseases (treatment) | Phase II |
| humanized rabbit mAb | IgG1 | APX005M | Apexigen, Epitomics | human CD40 | cancer (treatment) | Phase II |
| humanized rabbit mAb | aglycosylated IgG1 | clazakizumab (ALD518; BMS - 945429) | Vitaeris, Bristol-Myers Squibb, Alder | human IL-6 | inflammation (treatment) transplantation (treatment) | Phase II |
| humanized rabbit mAb | IgG1 | ontuxizumab (MORAb-004) | Morphotek | human CD248 | cancer (treatment) | Phase II |
| humanized rabbit mAb | IgG1 | SSS07 (APX001) | 3SBio, Apexigen, Epitomics | human TNFα | inflammation (treatment) | Phase I |
| humanized rabbit mAb | IgG1 | YYB101 | YooYoung | human HGF | cancer (treatment) | Phase I |
| rabbit mAb | scFv CAR-T | R12 | Fred Hutchinson Cancer Research Center | human ROR1 | cancer (treatment) | Phase I |
1
Only rabbit antibodies in clinical trials registered at ClinicalTrials.gov were included.
2
Abbreviations: IgG, immunoglobulin G; scFv, single-chain variable fragment; CAR-T, chimeric antigen receptor T cell.